Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Mantle-Cell 2Lymphoma, Non-Hodgkin 1Leukemia, B-Cell 1Leukemia 1

Interventions

Rituximab 3acalabrutinib 2Bendamustine Hydrochloride 2zanubrutinib 1venetoclax 1umbralisib 1ublituximab 1pirtobrutinib 1fludarabine 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Lenalidomide 1Cyclophosphamide 1Appointments and Schedules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Lymphoma, Mantle-Cell × acalabrutinib × Clear all
NCT02213926 2026-05-18

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Acerta Pharma BV

Phase 2 Active not recruiting
124 enrolled 10 charts 1 FDA
Lymphoid

Lymphoma, Mantle-Cell

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Acerta Pharma BV

Phase 3 Active not recruiting
635 enrolled 1 FDA
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡